Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. In this IO arena, we continue to search for additional treatments that can further benefit patients. While several subsets of T-cells exist, most can be classified as either CD8+ or CD4+ T-cells.
98 
Let's personalize your content